Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.

The prospective change in height SDS during one year of observation was positively associated with higher BAP and TRAP5b SDS, lower baseline height SDS and rhGH therapy.Interestingly, physical activity showed a positive association to prospective growth.A case-control study was performed to obtain an unbiased analysis of the impact of rhGH on the bone marker pattern. For 41 rhGH treated patients an equal number of untreated control subjects matched by age, sex, country of residence, CKD duration, eGFR and serum phosphorus, iPTH and CRP was identified (see Table 5).Predictors of baseline and prospective change in standardized height in total cohort; results of stepwise multiple linear regression analyses.

为期一年观察期内的预期身高标准差评分（height SDS）变化，与更高的骨碱性磷酸酶（BAP）、抗酒石酸酸性磷酸酶5b（TRAP5b）标准差评分、更低的基线身高标准差评分及重组人生长激素（rhGH）治疗呈正相关。值得注意的是，体力活动与预期生长同样存在正相关关系。本研究开展病例对照研究，旨在无偏地分析重组人生长激素（rhGH）对骨标志物谱的影响。共纳入41例接受rhGH治疗的患者，同时匹配了年龄、性别、居住国家、慢性肾脏病（CKD）病程、估算肾小球滤过率（eGFR）、血清磷、全段甲状旁腺激素（iPTH）及C反应蛋白（CRP）均匹配的同等数量未治疗对照受试者（详见表5）。全队列中基线身高及预期身高标准化变化的预测因素；逐步多元线性回归分析结果。